Researchers from DANDRITE have played a central role in developing a new oral treatment that, for the first time ever, has shown promising results in a clinical trial involving patients—a breakthrough that appears capable of preventing and slowing the progression of frontotemporal dementia.
This article was originally published on MedicalXpress.com

